GleamWall
中文EN

TVGN Tevogen Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1860871 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.3%
TTM EPS YoY23.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-571.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets421.4%
Debt / equity—
Current ratio0.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.43x
Accruals ratio-325.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.96M$3.28M$3.13M$2.11M$3.11M$2.70M$3.20M$2.84M
SG&A expense$3.94M$2.38M$2.27M$2.50M$2.62M$2.74M$7.16M$6.53M
Operating income-$6.90M-$5.66M-$5.40M-$4.61M-$5.73M-$5.44M-$10.36M-$9.36M
Interest expense——————$24,571$15,798
Net income-$7.00M-$5.76M-$5.45M-$4.68M-$5.73M-$5.50M-$10.37M-$9.44M
EBITDA-$6.89M-$5.63M-$5.37M-$4.55M-$5.73M-$5.35M-$10.32M-$9.32M
EPS (basic)-1.76-1.52-1.61—-1.50-1.71-3.25—
EPS (diluted)-1.76-1.52-1.61—-1.50-1.71-3.25—
Weighted avg. shares (diluted)4.10M3.83M3.49M—3.92M3.29M3.23M—
Banking
Net interest income-$99,950-$98,387-$71,166-$70,674-$62,340-$38,033-$24,571-$15,798
Balance sheet
Cash & equivalents$144,713$1.08M$692,305$552,372$1.04M$685,229$1.97M$1.28M
Current assets$841,136$2.01M$2.14M$1.54M$2.12M$2.06M$3.08M$2.36M
PP&E, net$95,539$109,772$140,040$170,308$163,930$164,448$255,889$296,442
Total assets$3.51M$4.73M$4.92M$4.38M$4.49M$4.27M$4.07M$3.46M
Current liabilities$6.37M$6.15M$7.27M$7.07M$6.74M$8.08M$8.72M$9.04M
Total liabilities$14.81M$13.62M$14.76M$12.62M$12.32M$13.75M$11.79M$10.14M
Shareholders' equity-$11.29M-$8.89M-$9.84M-$8.23M-$7.82M-$9.48M-$7.72M-$6.67M
Shares outstanding15.74M4.26M4.17M4.02M197.39M193.69M183.89M3.56M
Cash flow statement
Operating cash flow-$1.96M-$3.01M-$2.73M-$2.18M-$3.65M-$3.19M-$3.31M-$3.05M
Financing cash flow$1.02M$3.40M$2.87M$1.76M$4.00M$1.90M$4.00M$2.00M
Depreciation & amortization$14,233$30,268$30,268$58,061$518$91,441$40,553$40,552
Stock-based compensation$4.50M$3.29M$2.85M$2.45M$3.24M$3.24M$7.29M$6.96M

Free plan shows the latest 8 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.